Amneal Completes Hat Trick With Delayed $2.6bn US Pegfilgrastim Entry
Developed With Kashiv BioSciences, Fylnetra Is Sixth Biosimilar On The Market
With its pure partnered approach, US-based player Amneal has tallied up its third biosimilar launch in the market.
